Brief Report| Volume 62, ISSUE 9, P1059-1061, November 01, 2007

Further Evidence of Dopamine Transporter Dysregulation in ADHD: A Controlled PET Imaging Study Using Altropane


      The dopamine transporter (DAT) is known to be a key regulator of dopamine, and recent studies of genetics, treatment, and imaging have highlighted the role of DAT in attention-deficit/hyperactivity disorder (ADHD). The findings of in vivo neuroimaging of DAT in ADHD have been somewhat discrepant, however.


      Dopamine transporter binding was measured using a highly selective ligand (C-11 altropane) and positron emission tomography (PET). The sample consisted of 47 well-characterized, treatment-naïve, nonsmoking, non-comorbid adults with and without ADHD. Additionally, control subjects had few symptoms of ADHD.


      Results showed significantly increased DAT binding in the right caudate in adults with ADHD compared with matched control subjects without this disorder.


      These results confirm abnormal DAT binding in the striatum of adults with ADHD and provide further support that dysregulation of DAT may be an important component of the pathophysiology of ADHD.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bhatia K.P.
        • Marsden C.D.
        The behavioural and motor consequences of focal lesions of the basal ganglia in man.
        Brain. 1994; 117: 859-876
        • Biederman J.
        • Faraone S.V.
        • Spencer T.
        • Wilens T.
        • Norman D.
        • Lapey K.A.
        • et al.
        Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder.
        Am J Psychiatry. 1993; 150: 1792-1798
        • Faraone S.V.
        • Perlis R.H.
        • Doyle A.E.
        • Smoller J.W.
        • Goralnick J.
        • Holmgren M.A.
        • et al.
        Molecular genetics of attention deficit hyperactivity disorder.
        Biol Psychiatry. 2005; 57: 1313-1323
        • Hollingshead A.B.
        Four factor index of social status.
        Yale University Press, New Haven, CT1975
        • Jastak J.F.
        • Jastak S.
        The Wide Range Achievement Test—Revised.
        Jastak Associates, Wilmington, DE1985
        • Jucaite A.
        • Fernell E.
        • Halldin C.
        • Forssberg H.
        • Farde L.
        Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: Association between striatal dopamine markers and motor hyperactivity.
        Biol Psychiatry. 2005; 57: 229-238
        • Krause K.H.
        • Dresel S.H.
        • Krause J.
        • la Fougere C.
        • Ackenheil M.
        The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder.
        Neurosci Biobehav Rev. 2003; 27: 605-613
        • Madras B.K.
        • Miller G.M.
        • Fischman A.J.
        The dopamine transporter: Relevance to attention deficit hyperactivity disorder (ADHD).
        Behav Brain Res. 2002; 130: 57-63
        • Mozley L.H.
        • Gur R.C.
        • Mozley P.D.
        • Gur R.E.
        Striatal dopamine transporters and cognitive functioning in healthy men and women.
        Am J Psychiatry. 2001; 158: 1492-1499
        • Spencer T.
        • Adler L.
        Diagnostic approaches to adult attention-deficit/hyperactivity disorder.
        Primary Psychiatry. 2004; 11: 49-53
        • Spencer T.J.
        • Biederman J.
        • Ciccone P.E.
        • Madras B.K.
        • Dougherty D.D.
        • Bonab A.A.
        • et al.
        PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate.
        Am J Psychiatry. 2006; 163: 387-395
        • Spencer T.J.
        • Biederman J.
        • Madras B.K.
        • Faraone S.V.
        • Dougherty D.D.
        • Bonab A.A.
        • et al.
        In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: A focus on the dopamine transporter.
        Biol Psychiatry. 2005; 57: 1293-1300
        • Spencer T.
        • Biederman J.
        • Wilens T.
        • Faraone S.V.
        Overview and neurobiology of attention-deficit/hyeractivity disorder.
        J Clin Psychiatry. 2002; 63: 3-9
        • van Dyck C.H.
        • Malison R.T.
        • Jacobsen L.K.
        • Seibyl J.P.
        • Staley J.K.
        • Laruelle M.
        • et al.
        Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene.
        J Nucl Med. 2005; 46: 745-751
        • van Dyck C.H.
        • Seibyl J.P.
        • Malison R.T.
        • Laruelle M.
        • Zoghbi S.S.
        • Baldwin R.M.
        • Innis R.B.
        Age-related decline in dopamine transporters: Analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries.
        Am J Geriatr Psychiatry. 2002; 10: 36-43
        • Volkow N.D.
        • Ding Y.S.
        • Fowler J.S.
        • Wang G.J.
        • Logan J.
        • Gatley S.J.
        • et al.
        Dopamine transporters decrease with age.
        J Nucl Med. 1996; 37: 554-559
        • Wechsler D.
        Manual for the Wechsler Adult Intelligence Scale—Revised.
        Psychological Corporation, San Antonio1981